Summary
The epididymal, testicular, and prostatic tissue penetration of sparfloxacin, a new quinolone, was assessed in a rat model of acute epididymitis. Seventy-two hours after injection of 0.1 ml (106 cfu/ml) of anEscherichia coli suspension into the right epididymis via the right ductus deferens, a single oral dose of sparfloxacin 50 mg/kg body weight was administered. One, 2, 4, 8, 12, and 24 h after administration the animals were sacrificed and the sparfloxacin concentrations and “areas under the curve” (AUC0–24) in both epididymides, both testes, the prostate gland and in the serum were measured by bioassay. The highest mean AUC0–24 was found in the prostate gland, followed by left epididymis, right epididymis, serum, right testis, and left testis (190, 79, 60, 28, 12, and 9 mg/kg×h, respectively). Though there was no statistically significant difference in the sparfloxacin concentration of both epididymides (p=0.09), the mean AUC0–24 was significantly higher in the non-infected left epididymis (p<0.0001). The AUC0–24 and sparfloxacin concentrations of the right infected epididymis were significantly higher than those observed in the serum (p<0.0001). In both testes, the AUC0–24 and sparfloxacin concentrations were lower than in the serum (p<0.0001), however, the concentration exceeded the MIC tenfold for approximately 20 h. It is concluded that the pharmacokinetic properties of sparfloxacin (goodin vitro activity, high penetration into the prostate gland, testes, infected and non-infected epididymides) make this drug a recommendable choice for the initial treatment of acute epididymitis caused byE. coli.
Similar content being viewed by others
References
Krieger, J. N. Epididymitis, orchitis, and related conditions. Sex. Transm. Dis. 11 (1984) 173–181.
Melekos, M. D., Asbach, H. W. Epididymitis: aspects concerning etiology and treatment. J. Urol. 138 (1987) 83–86.
Berger, R. E., Alexander, E. R., Harnisch, J. P., Paulsen, C. A., Monda, G. D., Ansell, J., Holmes, K. K. Etiology, manifestations and therapy of acute epididymitis: prospective study of 50 cases. J. Urol. 121 (1979) 750–754.
Weidner, W., Garbe, Ch., Weißbach, L., Harbrecht, J., Kleinschmidt, K., Schiefer, H. G., Friedrich, H. J. Initiale Therapie der akuten einseitigen Epididymitis mit Ofloxacin. I. Klinische und mikrobiologische Befunde. Urologe A 29 (1990) 272–276.
Weidner, W., Garbe, Ch., Weißbach, L., Harbrecht, J., Kleinschmidt, K., Schiefer, H. G., Friedrich, H. J. Initiale Therapie der akuten einseitigen Epididymitis mit Ofloxacin. II. Andrologische Befunde. Urologe A 29 (1990) 277–280.
See, W. A., Taylor, T. O., Mack, L. A., Tartaglione, T. A., Opheim, K. E., Berger, R. E. Bacterial epididymitis in the rat: a model for assessing the impact of acute inflammation on epididymal antibiotic penetration. J. Urol. 144 (1990) 780–784.
Tartaglione, T. A., Taylor, T. O., Opheim, K. E., See, W. A., Berger, R. E. Antimicrobial tissue penetration in a rat model ofE. coli epididymitis. J. Urol. 146 (1991) 1413–1417.
Vieler, E., Jantos, C., Schmidts, J. L., Weidner, W., Schiefer, H. G. Comparative efficacies of ofloxacin, cefotaxime, and doxycycline for treatment of experimental epididymitis due toEscherichia coli in rats. Antimicrob. Agents Chemother. 37 (1993) 846–850.
Furuya, A., Kumamoto, Y., Sugiyama, S. Fine structure and development of Sertoli junctions in human testis. Arch. Androl. 1 (1978) 211–219.
Schlegel, P. N., Chang, T. S. K. The testis, epididymis and ductus deferens. In:Walsh, P. C., Retik, A. G., Stamey, T. A., Vaughan, E. D. (eds.): Campbell's urology. W. B. Saunders Company, Philadelphia, London, Toronto, Montreal, Sydney, Tokyo 1992, pp. 190–220.
Weidner, W., Schiefer, H. G., Garbe, C. Acute nongonococcal epididymitis. Aetiological and therapeutical aspects. Drugs 34 (Suppl. I) (1987) 111–117.
Matsunaga, Y., Miyazaki, H., Oh-e, Y., Nambu, K., Furukawa, H., Yoshida, K., Hashimoto, M. Disposition and metabolism of [14C)]sparfloxacin in the rat. Arzneim.-Forsch./Drug Res. 41 (1991) 747–757.
Cooper, M. A., Andrews, J. M., Ashby, J. P., Matthews, R. S., Wise, R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J. Antimicrob. Chemother. 26 (1990) 667–676.
Nakata, K., Maeda, H., Fujii, A., Arakawa, S., Umezu, K., Kamidono, S. In vitro andin vivo activities of sparfloxacin, other quinolones and tetracyclines againstChlamydia trachomatis. Antimicrob. Agents Chemother. 36 (1992) 188–190.
Rubinstein, E., Dautrey, S., Farinoti, R., St. Julien, L., Ramon, J., Carbon, C. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats. Antimicrob. Agents Chemother. 39 (1995) 99–102.
Nakamura, S., Kurobe, N., Ohue, T., Hashimoto, M., Shimizu, M. Pharmacokinetics of a novel quinolone, AT-4140, in animals. Antimicrob. Agents Chemother. 34 (1990) 89–93.
Schoenknecht, F. D., Sabath, L. D., Thornsberry, C. Susceptibility tests: special tests. In:Lennette, E. H., Balows, A., Hausler Jr., W. J., Shadomy, H. J. (eds.): Manual of clinical microbiology. American Society for Microbiology, Washington, D. C. 1985, pp. 1000–1008.
Nakamura, S., Kurobe, N., Kashimoto, S., Ohue, T., Takase, Y., Shimizu, M. Pharmacokinetics of AT-2266 administered orally to mice, rats, dogs, and monkeys. Antimicrob. Agents Chemother. 24 (1983) 54–60.
Dixon, M. J. (chief ed.): BMDP statistical software manual, Vol. 1 and 2. University of California Press, Berkely, Los Angeles, Oxford 1993.
Sachs, L. Applied statistics — a handbook of techniques. Springer Verlag, New York, Heidelberg, Berlin, 1982.
Kayser, F. H., Wüst, J. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 10 (1991) 163–166.
Berger, R. E. Epididymitis. In:Holmes, K. K., Mårdh, P. A., Sparling, P. J., Wiesner, P. J. (eds.): Sexually transmitted diseases. Mc Graw Hill, New York 1990, pp. 650–662.
Höppner, W., Strohmeyer, T., Hartmann, M., Lopez-Gamarra, D., Dreikorn, K. Surgical treatment of acute epididymitis and its underlying diseases. Eur. Urol. 22 (1992) 218–221.
Nielsen, O. S. An experimental study of the treatment of bacterial epididymitis. Scand. J. Urol. Nephrol. 104 (Suppl.) (1987) 732–737.
Krieger, J. N. New sexually transmitted diseases treatment guidelines. J. Urol. 154 (1995) 209–213.
Schentag, J. J., Gengo, F. M. Principles of antibiotic tissue penetration and guideline for pharmacokinetic analysis. Med. Clin. North. Am. 66 (1982) 39–49.
Weidner, W., Prudlo, J., Schiefer, H. G., Jantos, C., Altmannsberger, M., Aumüller, G. Escherichia coli-Epididymitis der Ratte: Ein tierexperimentelles Modell der akut-eitrigen und chronisch-obstruktiven Entzündung. Fertilität 5 (1989) 151–155.
Shimada, J., Nogita, T., Ishibashi, Y. Clinical pharmacokinetics of sparfloxacin. Clin. Pharmacokinet. 25 (1993) 358–369.
Madsen, P. O., Drescher, P., Gasser, T. C. Basis for antibacterial treatment of prostatitis: experimental and clinical pharmacokinetic studies and models. In:Weidner, W., Madsen, P. O., Schiefer, H. G. (eds.): Prostatitis. Springer, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, Barcelona, Budapest 1994, pp. 110–122.
Just, P. M. Overview of the fluoroquinolone antibiotics. Pharmacotherapy 13 (1993) 4–17.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ludwig, M., Wolf, S., Weidner, W. et al. Tissue penetration of sparfloxacin in a rat model of experimentalEscherichia coli epididymitis. Infection 25, 178–184 (1997). https://doi.org/10.1007/BF02113609
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02113609